Skip to search formSkip to main contentSkip to account menu

trabectedin

A tetrahydroisoquinoline alkaloid isolated from the marine tunicate Ecteinascidia turbinata with potential antineoplastic activity. Binding to the… 
National Institutes of Health

Related topics

Related topics

9 relations
Alkylating Activity [MoA]NCIt Antineoplastic Agent Terminologytrabectedin 1 MG Injection [Yondelis]

Broader (3)

Antineoplastic Agents, AlkylatingDioxolesTetrahydroisoquinolines

Narrower (3)

Ecteinascidin 743NSC 684766Yondelis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials
Background:This retrospective pooled analysis assessed the effect of age on the efficacy and safety of trabectedin in young and… 
2013
2013
Analysis of DNA Repair–Related Genes in Breast Cancer Reveals CUL4A Ubiquitin Ligase as a Novel Biomarker of Trabectedin Response
Trabectedin is more active in nucleotide excision repair (NER)-efficient and homologous recombination repair (HRR)-deficient… 
Review
2011
Review
2011
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis
PurposeThis analysis provides a cross-study evaluation of the cardiac safety of trabectedin.MethodsDrug-related cardiac adverse… 
2010
2010
Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
Soft tissue sarcoma (STS) comprises a large variety of rare malignant tumors. Development of distant metastasis is frequent, even… 
2010
2010
Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients
Trabectedin is a tetrahydro-isoquinoline alkaloid isolated from a tunicate (Ecteinascidia turbinata) that binds and alkylates N2… 
Review
2009
Review
2009
Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas: Report on Five Patients and a Review of the Literature
Abstract The clinical impact of ET-743 (trabectedin; Yondelis) in women with leiomyosarcoma and undifferentiated uterine sarcoma… 
Review
2008
Review
2008
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
BACKGROUND Patients with advanced or metastatic non-gastrointestinal stromal tumour soft tissue sarcoma (STS) whose disease… 
2008
2008
Trabectedin and its potential in the treatment of soft tissue sarcoma
Trabectedin is a new marine-derived compound that binds the DNA minor groove and interacts with proteins of the DNA repair… 
Review
2008
Review
2008
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma
Background: Patients with advanced or metastatic non-gastrointestinal stromal tumour soft tissue sarcoma (STS) whose disease… 
2005
2005
Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer
Trabectedin (YondelisTM, formerly ET-743) is an anti-cancer drug currently undergoing phase II development. Despite extensive… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)